Literature DB >> 31552530

The role of additional hysterectomy after concurrent chemoradiation for patients with locally advanced cervical cancer.

Kosuke Yoshida1, Hiroaki Kajiyama2, Masato Yoshihara1, Satoshi Tamauchi1, Yoshiki Ikeda1, Nobuhisa Yoshikawa1, Kimihiro Nishino1, Kaoru Niimi1, Shiro Suzuki1, Fumitaka Kikkawa1.   

Abstract

BACKGROUND: The standard treatment for cervical cancer is chemoradiation although some patients showed treatment resistance. The purpose of this study was to investigate the clinical efficacy of surgery after chemoradiation for cervical cancer.
METHODS: Patients with FIGO stage IB2 to IIB cervical cancer were included in the study between 2005 and 2015. A total of 50 patients who underwent surgery after neoadjuvant chemoradiation and 76 patients who received only chemoradiation were compared. Baseline differences between the two groups were adjusted with inverse probability of treatment weighting method using propensity scores composed of the following independent variables: age, stage, tumor size, lymph node metastasis, and histological subtypes.
RESULTS: Median follow-up was 64.8 (range 4.8-143.9) months. After adjustment with inverse probability of treatment weighting, Kaplan-Meier curves showing adjusted progression-free survival and overall survival were significantly longer in the neoadjuvant chemoradiation compared with the chemoradiation-only group (p = 0.027 and p = 0.017, respectively). Moreover, in patients with squamous cell carcinoma, recurrence in previously irradiated field and recurrence both in and out of previously irradiated field were significantly decreased in the neoadjuvant chemoradiation compared with the chemoradiation-only group (3.1% and 18.4%, respectively; OR 0.142, p = 0.001]. Adverse events of surgery after chemoradiation were acceptable, although temporary hydronephrosis was frequently observed (23.1%).
CONCLUSIONS: Surgery after chemoradiation reduced pelvic recurrence, and as a result, patients who underwent neoadjuvant chemoradiation showed more favorable survival outcomes compared with those who only underwent chemoradiation.

Entities:  

Keywords:  Chemoradiation; Inverse probability of treatment weighting; Locally advanced cervical cancer; Neoadjuvant therapy; Propensity score; Surgery

Mesh:

Year:  2019        PMID: 31552530     DOI: 10.1007/s10147-019-01551-6

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  32 in total

1.  Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy: results of a multicenter study.

Authors:  D Hequet; E Marchand; V Place; V Fourchotte; A De La Rochefordière; S Dridi; C Coutant; F Lecuru; A-S Bats; M Koskas; J-J Bretel; A Bricou; Y Delpech; E Barranger
Journal:  Eur J Surg Oncol       Date:  2013-10-23       Impact factor: 4.424

2.  High-dose-rate brachytherapy and concurrent chemoradiotherapy followed by surgery for stage Ib-IIb cervical cancer: single institution experience.

Authors:  Ana Fröbe; Glenn Jones; Tomislav Bokulić; Iva Mrčela; Mirjana Budanec; Jure Murgić; Blanka Jakšić; Marin Prpić; Ante Bolanča; Zvonko Kusić
Journal:  Anticancer Res       Date:  2014-07       Impact factor: 2.480

Review 3.  Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials.

Authors:  Andrew Anglemyer; Hacsi T Horvath; Lisa Bero
Journal:  Cochrane Database Syst Rev       Date:  2014-04-29

4.  A post-recurrence survival-predicting indicator for cervical cancer from the analysis of 165 patients who developed recurrence.

Authors:  Kosuke Yoshida; Hiroaki Kajiyama; Fumi Utsumi; Kaoru Niimi; Jun Sakata; Shiro Suzuki; Kiyosumi Shibata; Fumitaka Kikkawa
Journal:  Mol Clin Oncol       Date:  2017-12-08

5.  Prognostic factors and morbidities after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer.

Authors:  Cyril Touboul; Catherine Uzan; Audrey Mauguen; Sebastien Gouy; Annie Rey; Patricia Pautier; Catherine Lhommé; Pierre Duvillard; Christine Haie-Meder; Philippe Morice
Journal:  Oncologist       Date:  2010-03-23

Review 6.  Cervical cancer.

Authors:  Steven E Waggoner
Journal:  Lancet       Date:  2003-06-28       Impact factor: 79.321

7.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.

Authors:  H M Keys; B N Bundy; F B Stehman; L I Muderspach; W E Chafe; C L Suggs; J L Walker; D Gersell
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

8.  Surgical principles for managing stage IB2, IIA2, and IIB uterine cervical cancer (Bulky Tumors) in Japan: a survey of the Japanese Gynecologic Oncology Group.

Authors:  Mikio Mikami; Yoichi Aoki; Masaru Sakamoto; Muneaki Shimada; Nobuhiro Takeshima; Hisaya Fujiwara; Takashi Matsumoto; Tunekazu Kita; Ken Takizawa
Journal:  Int J Gynecol Cancer       Date:  2014-09       Impact factor: 3.437

9.  Neoadjuvant chemotherapy followed by surgery has no therapeutic advantages over concurrent chemoradiotherapy in International Federation of Gynecology and Obstetrics stage IB-IIB cervical cancer.

Authors:  Jeongshim Lee; Tae Hyung Kim; Gwi Eon Kim; Ki Chang Keum; Yong Bae Kim
Journal:  J Gynecol Oncol       Date:  2016-06-08       Impact factor: 4.401

10.  Feasibility of radical hysterectomy in women with FIGO stage IIB cervical cancer: an observation study of 10-year experience in a tertiary center.

Authors:  Lei Yuan; Jiaqi Guo; Xiaochun Zhang; Mo Chen; Congjian Xu; Liangqing Yao
Journal:  Onco Targets Ther       Date:  2018-09-19       Impact factor: 4.147

View more
  3 in total

1.  Usefulness of Short-Term Imaging and Squamous Cell Carcinoma Antigen to Early Predict Response to Concurrent Chemoradiotherapy in Patients With Cervical Cancer.

Authors:  Ji Geun Yoo; Sang Il Kim; Seung Geun Yeo; Dong Choon Park
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

2.  A comparative analysis of high-flux and low-flux dialysis in cervical cancer patients with obstructive renal failure showing no significantly improved renal function after catheterisation.

Authors:  Chen-Li Zhang; De-Qiong Xie; Li-Na Ao; Lei Zhu
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 1.088

3.  Successful treatment of locally advanced bulky cervical cancer complicated by irreducible complete uterine prolapse: A case report.

Authors:  Dong Hyung Lee; Jong Kil Joo; Dong Soo Suh; Byung Sup Shin; Seo Yoon Hwang; Ki Hyung Kim
Journal:  Medicine (Baltimore)       Date:  2022-01-21       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.